Last reviewed · How we verify

Anthrex — Competitive Intelligence Brief

Anthrex (PROQUAZONE) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: proquazone. Area: Other.

phase 2 proquazone Epidermal growth factor receptor, Prostaglandin G/H synthase 1, Prostaglandin G/H synthase 2 Other Small molecule Live · refreshed every 30 min

Target snapshot

Anthrex (PROQUAZONE). Proquazone works by directly interacting with the Epidermal Growth Factor Receptor (EGFR) to potentially inhibit its activity.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Anthrex TARGET PROQUAZONE phase 2 proquazone Epidermal growth factor receptor, Prostaglandin G/H synthase 1, Prostaglandin G/H synthase 2

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (proquazone class)

  1. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Anthrex — Competitive Intelligence Brief. https://druglandscape.com/ci/proquazone. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing